OncoC4 to Present Late-Breaking Data on Cesalatamig at SITC 41st Annual Meeting

OncoC4 to Present Late-Breaking Data on Cesalatamig at the 41st Annual SITC Meeting

OncoC4 Inc., a prominent player in the field of biopharmaceuticals, is set to unveil crucial findings regarding their innovative therapy, cesalatamig (AI-081), at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This late-breaking abstract highlights significant results from global Phase 1/2 clinical trials focusing on patients with non-small cell lung cancer (NSCLC) who have shown resistance to PD-(L)1 inhibitors.

Scheduled for November 7, 2026, Dr. Kai He, an esteemed professor of hematology and oncology and the leading investigator for the BiPAVE-001 trials, will present the latest insights into the safety and efficacy of the bispecific antibody cesalatamig. This presentation will occur during Clinical Oral Abstract Session 2, starting at 1:45 PM MST (UTC−7). The details outlined in Abstract #1187 will unveil important clinical data derived from the ongoing BiPAVE-001 studies focusing on patients whose NSCLC has resisted conventional PD-(L)1 therapies.

Cesalatamig, a bispecific antibody targeting PD-1 and VEGF, has been intricately designed to enhance cooperative interactions between these pathways, demonstrating superior binding affinity when compared to existing bevacizumab-based PD-(L)1/VEGF combinations. As a result, this groundbreaking treatment holds substantial promise in optimizing therapeutic effectiveness within a tumor microenvironment characterized by high levels of PD-1 and VEGF. Furthermore, cesalatamig boasts advanced FC-silencing modifications, which prevent the depletion of PD-1-positive T cells, a significant advantage in maintaining effective immune responses against cancer.

In a significant regulatory milestone, cesalatamig received Fast Track designation from the U.S. FDA in September 2026, acknowledging its potential in treating NSCLC that has progressed following standard immunotherapies and chemotherapy. This designation positions OncoC4 favorably as they continue to conduct pivotal research aimed at improving treatment outcomes for patients battling advanced solid tumors.

The BiPAVE-001 trials, currently underway in both the U.S. and China, not only assess the safety and pharmacokinetics of cesalatamig but also explore its efficacy as a monotherapy and in combination with established treatments. These trials consist of two principal segments; the initial Phase 1 part focuses on dose escalation and expansion, while the latter Phase 2 aspect involves optimizing dosages for various approved indications.

Based at Rockville, Maryland, OncoC4 remains at the forefront of developing novel therapies for cancer and autoimmune diseases. The company prides itself on its strong pipeline, showcasing both first-in-class and best-in-class candidates targeting well-established and emerging therapeutic targets. The ongoing development of cesalatamig represents a key aspect of OncoC4's commitment to transforming cancer treatment and enhancing patients' quality of life.

As the date of presentation approaches, excitement builds around the potential implications of cesalatamig's findings. With a focus on advancing the understanding of treatment-resistant NSCLC, OncoC4 is poised to contribute significantly to the evolving landscape of cancer immunotherapy.

For further updates and information, you can visit OncoC4's official website.